Sunday Mar 2
New Study Validates NephroCheckA Test For Risk Of Acute Kidney Injury
The NephroCheckA Test, developed by Astute Medical, Inc., utilizes fluorescence immunoassay technology to detect and measure two biomarkers of AKI, tissue inhibitor of metalloproteinase 2 and insulin-like growth factor binding protein 7 in human urine.
Astute Medical To Host Kidney Injury Symposium
Event participants and others can follow the live event via Twitter @ACuteKidneyMan.